Dermavant to present phase 3 results of tapinarof cream

[Fred]

Tapinarof is a potential first-in-class, steroid-free, cosmetically elegant, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed for the treatment of plaque psoriasis and atopic dermatitis. To date, over 2,200 subjects have enrolled in 18 clinical trials of tapinarof.

Quote:

---

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two posters on tapinarof will be presented during the upcoming 2020 Fall Clinical Dermatology Conference to be held virtually Oct. 29-Nov. 1, 2020. The two presentations will cover data from Dermavant’s successful Phase 3 PSOARING pivotal trials in addition to a maximal use pharmacokinetics study.

“Having recently reported positive Phase 3 PSOARING 1 and PSOARING 2 results for tapinarof cream 1% in adult patients with plaque psoriasis, we are excited to share these efficacy and safety data at Fall Clinical,” said David Rubenstein, MD, PhD, Chief Scientific Officer of Dermavant. “These study outcomes reinforce the potential, subject to approval by the U.S. Food and Drug Administration, of tapinarof, a non-steroidal topical cream, to become a first-line treatment option for patients with plaque psoriasis. I would like to thank everyone who has been involved in the PSOARING program.”

Source: dermavant.com

[jiml]

This sounds very interesting and hopefully will get approval for use soon after the trials are finished
good to see its non steroid and hopefully can be used long term without skin damage